Quantcast
Channel: MIMS Ireland – Irish Medical Times
Viewing all articles
Browse latest Browse all 461

Combined Oral Contraception available in Ireland

$
0
0
Bookmark and Share

Table 1: Combined Oral Contraception (COC) available in Ireland

Synthetic progestogen (progestin)* Brand Dosage oestrogen / progestogen* Reimbursed price (one month supply unless otherwise stated)
**********************************  SECOND GENERATION *****************************************************************
Levonorgestrel

MICROLITE 20mcg / 100mcg 21, €4.05
LEONORE 20mcg / 100mcg 63, €9.47 (3 months)
OVRANETTE 30mcg / 150mcg 21, €0.77
LOGYNON 30/50mg; 40/75mcg; 30/125mcg 21, €4.01
**********************************  THIRD GENERATION ******************************************************************
Desogestrel MERCILON 20mcg / 150mcg 63, €10.71 (3 months)
MARVIOL 30mcg / 150mcg 63, €8.93 (3 months)
Gestodene MINULET 30mcg / 75mcg 63, €7.06 (3 months)
ESTELLE 30mcg / 75mcg 21, €2.31
Norgestimate CILEST 35mcg /250mcg 21, €0.94
**********************************  FOURTH GENERATION *****************************************************************
Drospirenone

YASMIN 30mcg / 3mg 21, €6.08
YASMINELLE 20mcg / 3mg 21, €7.02
YAZ 20mcg / 3mg 28 (24 + 4 inert), €8.60
Dienogest QLAIRA 3mg; 2mg/2mg; 2mg/3mg; 1mg 28 (26 + 2 inert), €9.17
Nomegestrol ZOELY 1.5mg / 2.5mg 28 (24 + 4 inert),  €8.35

*All combination birth control pills contain oestrogen (typically ethinyloestradiol, except for Qlaira and Zoely where it is oestradiol) and a progestin. The term progestin is used for any natural or man-made substance that has properties similar to natural progesterone. In contrast to oestrogen, there are many types of progestin found in various oral contraceptive brands. The older progestin types are usually referred to as first- and second-generation while the newer ones are called third- and fourth generation.

The progestogen component of Dianette, the anti-androgen cyproterone acetate, supresses ovulation and therefore also has a contraceptive effect, but due to known risk of thromboembolism Dianette is now indicated solely in the treatment of moderate to severe acne related to androgen sensitivity or hirsutism in women of reproductive age.

Classification of progestins

Most of these synthetic progestins are chemical derivatives of testosterone (known as 19-nortestosterone derivatives) and can be divided into two families: estrane and gonane. They include:

First generation progestins which consist of norethindrone and other progestins that metabolize to norethindrone (not marketed in Ireland). They belong to the estrane family.

Second generation progestins, which include levonorgestrel, have varying degrees of androgenic and oestrogenic activities. They are more androgenic than the first-generation progestins, which are in turn more androgenic than newer progestins, like desogestrel. They belong to the gonane family.

Newer gonanes, or third generation progestins include desogestrel, gestodene and norgestimate, which also belong to the gonane family. They are reported to have fewer androgenic effects.

The newest (fourth) generation include drospirenone, dienogest, and nomegestrol. Drospirenone is a unique progestin as it differs from the others because it is derived from 17a-spirolactone, not from the 19-nortestosterone derivatives.

Typically the third and fourth generation progestins tend to be highly selective and possess minimal androgenic properties.

NB: Higher androgenic activity may increase the chances of androgen-related side effects which mainly include acne and hirsutism. Also, progestins with less androgenic activity tend to have little to no effect on carbohydrate metabolism. A higher amount of oestrogenic activity helps to decrease androgen-related side effects.


Practical advice for practitioners on VTE risk
  • Health professionals should be aware the risk of venous thromboembolism (VTE) amongst COC users is approximately twice that of non-users (average across all brands studied). The risk of VTE associated with newer progestogens such as desogestrel, drospirenone and gestodene has, in several but not all studies been found to be higher than the risk associated with levonorgestrel-containing pills and up to six times that of non-contraceptive users. However, women should be aware that the absolute risk for all combined hormonal contraceptives is still very low (approx. 1/1,000), and three times lower than in pregnancy (approx. 3/1,000).
  • Women starting combined hormonal contraception should be offered a levonorgestrel-containing combined oral contraceptive as a first line option.
  • In addition to considering the risk of VTE, health professionals prescribing CHCs should take into account the individual woman’s personal preference, risk factors, any contraindications, potential non-contraceptive benefits and experience with other contraceptive formulations.

Reference: 1- Risk of venous thromboembolism in users of non-oral contraceptives. Statement from the Faculty of Sexual and Reproductive Healthcare (FSRH). Available at: http://www.fsrh.org/pdfs/CEUstatementVTEandCHC.pdf. Accessed 15 August 2013.


Download Pdf


MIMS Ireland Copyright®


Viewing all articles
Browse latest Browse all 461

Trending Articles